Effect of CYP2C8 inhibition by trimethoprim on the pharmacokinetics of rosiglitazone.

被引：0
|
作者：
Hruska, MW [1 ]
Amico, JA [1 ]
Frye, RF [1 ]
机构：
[1] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2003年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
92
引用
收藏
页码：1036 / 1036
页数：1
相关论文
共 50 条
  • [21] RIVOGLITAZONE (CS-011) PHARMACOKINETICS ARE AFFECTED BY COADMINSTRATION OF THE POTENT CYP2C8 INHIBITOR GEMBROZIL BUT NOT CYP2C8 GENOTYPES.
    Wickremasingha, P. K.
    Mendell, J.
    He, L.
    Mun, Y.
    Izumi, T.
    Allison, M. J.
    Walker, J. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S48 - S48
  • [22] The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide
    Bidstrup, TB
    Damkier, P
    Olsen, AK
    Ekblom, M
    Karlsson, A
    Brosen, K
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (01) : 49 - 57
  • [23] The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast
    Karonen, Tiina
    Neuvonen, Pertti J.
    Backman, Janne T.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (02) : 151 - 155
  • [24] The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast
    Tiina Karonen
    Pertti J. Neuvonen
    Janne T. Backman
    European Journal of Clinical Pharmacology, 2011, 67 : 151 - 155
  • [25] The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects
    Niemi, M
    Kajosaari, LI
    Neuvonen, M
    Backman, JT
    Neuvonen, PJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (04) : 441 - 447
  • [26] Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
    Aquilante C.L.
    Bushman L.R.
    Knutsen S.D.
    Burt L.E.
    Rome L.C.
    Kosmiski L.A.
    Human Genomics, 3 (1) : 7 - 16
  • [27] Evaluation of the Relationship Between Polymorphisms in CYP2C8 and CYP2C9 and the Pharmacokinetics of Celecoxib
    Prieto-Perez, Rocio
    Ochoa, Dolores
    Cabaleiro, Teresa
    Roman, Manuel
    Sanchez-Rojas, Sergio Daniel
    Talegon, Maria
    Abad-Santos, Francisco
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (12): : 1261 - 1267
  • [28] Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers
    Topletz-Erickson, Ariel R.
    Lee, Anthony
    Sun, Hao
    Mayor, JoAl
    Walker, Luke
    Endres, Christopher J.
    CANCER RESEARCH, 2020, 80 (16)
  • [29] Effect of St. John's wort administration on CYP2C8 mediated rosiglitazone metabolism.
    Hruska, MW
    Cheong, JA
    Langaee, TY
    Frye, RF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P35 - P35
  • [30] CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population
    Saito, Yoshiro
    Katori, Noriko
    Soyama, Akiko
    Nakajima, Yukiko
    Yoshitani, Takashi
    Kim, Su-Ryang
    Fukushima-Uesaka, Hiromi
    Kurose, Kouichi
    Kaniwa, Nahoko
    Ozawa, Shogo
    Kamatani, Naoyuki
    Komamura, Kazuo
    Kamakura, Shiro
    Kitakaze, Masafumi
    Tomoike, Hitonobu
    Sugai, Kenji
    Minami, Narihiro
    Kimura, Hideo
    Goto, Yu-ichi
    Minami, Hironobu
    Yoshida, Teruhiko
    Kunitoh, Hideo
    Ohe, Yuichiro
    Yamamoto, Noboru
    Tamura, Tomohide
    Saijo, Nagahiro
    Sawada, Jun-Ichi
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (07): : 461 - 471
12345